<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25809304</article-id><article-id pub-id-type="pmc">4409586</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2014598144</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000001491</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>19</subject><subject>41</subject><subject>319</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kuhle</surname><given-names>Jens</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) Genzyme (2) Protagen (3) Roche (4) Novartis</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>1. ECTRIMS Research Fellowship programme, 2012, 2013 2. Research funds of the university of Basel, 2012, 2013, 2014</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Disanto</surname><given-names>Giulio</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>BMC Neurology, Associate Editor, 2013</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>FISM Fondazione Italiana Sclerosi Multipla-research fellowship-Cod.:2010/B/5</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Lorscheider</surname><given-names>Johannes</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>Novartis, Funding for travel</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Stites</surname><given-names>Tracy</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Employee of Novartis Pharmaceuticals as a Clinical Scientific Director for the past 13 years. As an employee of Novartis I receive stock and/or stock options.</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Yu</given-names></name><degrees>MS</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Dahlke</surname><given-names>Frank</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Novartis Pharma AG, Basel, Switzerland Global Program Medical Director 8 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Francis</surname><given-names>Gordon</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Novartis, Clinical Development, 5 years ended in September 2014. Now retired.</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>Novartis</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>Novartis stock related to employment status with Novartis</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Shrinivasan</surname><given-names>Anupama</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>Dr A Shrinivasan is an employee of Novartis Healthcare Pvt Ltd, Hyderabad, India.,Clinical Scientific Expert,7 years</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Radue</surname><given-names>Ernst-Wilhelm</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>Dr. Radue received speaker honoraria and and travel compensation from Bayer Schering, Biogen Idec, Genzyme, Novartis, Merck-Serono, MorphoSys, Synthon.</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Dr. Radue received consultancy fees from Bayer-Schering, Biogen Idec, Genzyme, Novartis, Merck-Serono, Synthon, MorphoSys.</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Dr. Radue received institutional research support from Novartis, Biogen Idec, Actelion, Basilea, SAKK, Synarc.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Giovannoni</surname><given-names>Gavin</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1)Biogen-Idec (2) Fiveprime (3) Genzyme (4) GW Pharma (5) Ironwood (6) Merck-Serono (7) Novartis (8) Roche (9) Sanofi-Aventis (10) Synthon BV (11) Teva (12) Vertex Pharmaceuticals (13) Abbvie (14) Canbex</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>Speaker honoraria: (1)Biogen-Idec (2) Genzyme (3) GW Pharma (4) Merck-Serono (5) Novartis (6) Roche (7) Teva</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Multiple Sclerosis and Related Disorders, Editor since 2011</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>(1)Biogen-Idec (2) Fiveprime (3) Genzyme (4) GW Pharma (5) Ironwood (6) Merck-Serono (7) Novartis (8) Roche (9) Sanofi-Aventis (10) Synthon BV (11) Teva (12) Vertex Pharmaceuticals (13) Abbvie (14) Canbex</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>(1) Novartis (2) Teva</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Genzyme 2012-2014 Merck 2012-2014</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Kappos</surname><given-names>Ludwig</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1)Multiple Sclerosis Journal, (2)Multiple Sclerosis and Related Disorders (3)Journal of Neurology</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>all less than 500 USD</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1)Actelion, (2)Addex,(3)Bayer Health Care,(4)Biogen Idec, (5)Biotica, (6)CSL Behring, (7)Genzyme,(8)Lilly,(9) Merck Serono, (10)Mitsubishi, (11)Novartis,(12)Ono Pharma, (13)Pfizer, (14) Receptos, (15) Roche, (16)Sanofi- aventis, (17)Santhera, (18)Siemens, (19)Teva, (20)UCB, (21)Xenoport I have also lectured at medical conferences or in public on various aspects of the diagnosis and management of multiple sclerosis. In many cases these talks have been sponsored by non-restricted educational grants from one or another of the above listed companies. Honoraria and other payments for all these activities have been exclusively used for funding of research of my department. Research and the clinical operations (nursing and patient care services) of the MS Center in Basel have been supported by non-restricted grants from one or more of these companies.</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Research support by the Swiss National Research Foundation and the European Union</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>The Swiss MS Society and Novartis and Roche Research Foundations.</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><aff>From the Neuroimmunology Unit (J.K., G.D., G.G.), Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK; Neurology, Departments of Medicine, Clinical Research and Biomedicine (J.K., J.L., L.K.), and the Medical Image Analysis Center (MIAC) (E.-W.R.), University Hospital, Basel, Switzerland; Novartis Pharmaceuticals Corporation (T.S., Y.C., G.F.), East Hanover, NJ; Novartis Pharma AG (F.D.), Basel, Switzerland; and Novartis Healthcare Pvt Ltd (A.S.), Hyderabad, India.</aff></contrib-group><author-notes><corresp>Correspondence to Dr. Kuhle: <email>jens.kuhle@usb.ch</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by institutional funding (University Hospital Basel).</p></fn></author-notes><pub-date pub-type="ppub"><day>21</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>4</month><year>2015</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. --><volume>84</volume><issue>16</issue><fpage>1639</fpage><lpage>1643</lpage><history><date date-type="received"><day>26</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2015 American Academy of Neurology</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="NEUROLOGY2014598144.pdf"/><abstract><sec><title>Objective:</title><p>We assessed CSF levels of the light chain subunit of neurofilaments (NfL) at baseline and after fingolimod therapy or placebo in patients with relapsing-remitting multiple sclerosis (RRMS). Changes in NfL levels were also correlated with relapse and MRI outcomes.</p></sec><sec><title>Methods:</title><p>CSF samples were available, at baseline and 12 months after treatment initiation, from a subset of 36 patients with RRMS (fingolimod 0.5 mg: n = 9; fingolimod 1.25 mg: n = 15; placebo: n = 12) participating in the 2-year, phase 3 Fingolimod (FTY720) Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. NfL levels were determined in a blinded fashion using a commercial ELISA kit.</p></sec><sec><title>Results:</title><p>Median NfL levels did not differ between treatment groups at baseline (0.5 mg: 644 pg/mL; 1.25 mg: 659 pg/mL; pooled 0.5/1.25 mg: 652 pg/mL, placebo: 886 pg/mL; <italic>p</italic> value [fingolimod vs placebo] = 0.619, 0.495, and 0.481, respectively). Following 12 months of treatment, median changes from baseline in NfL levels were lower than zero in the fingolimod groups (0.5 mg: &#x02212;346 pg/mL, <italic>p</italic> = 0.039; 1.25 mg: &#x02212;313 pg/mL, <italic>p</italic> = 0.035) and pooled 0.5/1.25 mg fingolimod group (&#x02212;326 pg/mL, 83.3% with reduction, <italic>p</italic> = 0.002) but not in the placebo group (&#x02212;214 pg/mL, 66.7% with reduction, <italic>p</italic> = 0.388). Reductions in NfL levels at month 12 correlated with an improvement in relapse and MRI outcomes.</p></sec><sec><title>Conclusions:</title><p>Our results suggest a beneficial effect of fingolimod on this marker of axonal injury and support the utility of NfL as a quantitative biomarker in multiple sclerosis.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Neurofilaments (Nf) are neuronal structural proteins composed of 4 subunits: the triplet of Nf-light (NfL), Nf-medium, and Nf-heavy (NfH) chains, and &#x003b1;-internexin in the CNS, or peripherin in the peripheral nervous system. Nf subunits have emerged as promising biomarkers of axonal injury in multiple neurologic disorders.<sup><xref rid="R1" ref-type="bibr">1</xref></sup></p><p>Progressive neurodegeneration occurring secondary to inflammation and primary neurodegeneration is a hallmark of multiple sclerosis (MS) and a key contributor to disability progression.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> There is a need for soluble, quantitative biomarkers that could provide an early indication of neurodegeneration and response to therapies.</p><p>In MS, increased CSF levels of NfL and NfH have been reported in all stages of the disease.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> A recent, uncontrolled study reported significant reductions in CSF NfL and NfH levels in response to natalizumab therapy. Changes in NfL levels were more pronounced than NfH.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup></p><p>Fingolimod 0.5 mg once-daily (Gilenya, Novartis Pharma AG, Basel, Switzerland), a sphingosine-1-phosphate receptor modulator, is the first oral therapy approved for relapsing-remitting MS (RRMS). Preclinical findings<sup><xref rid="R6" ref-type="bibr">6</xref></sup> and consistent effects on brain atrophy observed in 3 phase III MS clinical trials<sup><xref rid="R7" ref-type="bibr">7</xref><xref ref-type="bibr" rid="R8">&#x02013;</xref><xref rid="R9" ref-type="bibr">9</xref></sup> suggest fingolimod has potential neuroprotective properties.</p><p>Here we report the effects of fingolimod on CSF NfL levels in RRMS compared with placebo. We also explored correlations between CSF NfL with clinical and imaging outcomes in placebo and fingolimod-treated patients, separately and combined.</p><sec sec-type="methods" id="s1"><title>METHODS</title><p>This was a post hoc investigation of NfL in CSF samples collected at baseline and month 12 in a subgroup of patients with RRMS participating in the 2-year, placebo-controlled, phase 3 Fingolimod (FTY720) Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> number, NCT00289978) that evaluated fingolimod at the doses of 0.5 mg and 1.25 mg once daily.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Provision of CSF samples was an optional component of the FREEDOMS study protocol. Definitions and methodologies of clinical and MRI assessments have been described previously.<sup><xref rid="R7" ref-type="bibr">7</xref></sup></p><p>CSF samples were available from 36 patients (0.5 mg, n = 9; 1.25 mg, n = 15; placebo, n = 12). CSF NfL levels were measured using the Uman Diagnostics NF-light ELISA kit (Ume&#x000e5;, Sweden). The assay was conducted blinded to the clinical data and treatment allocation.<sup><xref rid="R3" ref-type="bibr">3</xref><xref ref-type="bibr" rid="R4">&#x02013;</xref><xref rid="R5" ref-type="bibr">5</xref></sup> Interassay and intra-assay variability (coefficients of variation) in 3 longitudinal control samples were below 15%.</p><sec id="s1-1"><title>Standard protocol approvals, registrations, and patient consents.</title><p>Protocol approvals and registration details have been described previously.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> The study was approved by the local institutional review boards. All patients provided written informed consent.</p></sec><sec id="s1-2"><title>Statistical analysis.</title><p>Variables are described as medians (interquartile range) or numbers and percentages. The Mann-Whitney test was used for between-group comparisons (0.5 mg, 1.25 mg, and pooled fingolimod-treated [0.5 mg and 1.25 mg] vs placebo). In addition, we performed an analysis of covariance (ANCOVA) on rank transformed data (rank analysis of covariance) adjusted for treatment and baseline NfL levels as a sensitivity analysis for between-group comparison at month 12. The sign test was used to evaluate longitudinal comparisons, i.e., to test whether the median for change from baseline is different from zero. Correlations were analyzed using the Spearman correlation methodology. Correlation analyses on endpoints at the same time points were based on data pooled from the 3 treatment arms. Correlation analyses on endpoints from different time points, e.g., at baseline vs at month 12, were based on data pooled from both doses of fingolimod (0.5 mg and 1.25 mg) and data from the placebo arm separately in order to avoid the confounding effect from the treatment. A 2-sided <italic>p</italic> value &#x0003c;0.05 was considered significant. All analyses were conducted using SPSS (version 20, Chicago, IL) and GraphPad Prism 6.04 (GraphPad Software, San Diego, CA).</p><p>One patient discontinued from the fingolimod 1.25 mg group due to an adverse event (increased liver enzymes) after 6.4 months on treatment (patient Y).</p></sec></sec><sec sec-type="results" id="s2"><title>RESULTS</title><p>Baseline and study characteristics of the 36 patients evaluated in this study are presented in the <xref ref-type="table" rid="T1">table</xref>. The median time since onset of the last relapse to baseline was 159 days (122&#x02013;277). During the study, 3 patients on placebo experienced a total of 5 relapses. Two patients in the fingolimod groups reported one confirmed relapse each, and 1 patient in the fingolimod 1.25 mg group experienced 2 confirmed relapses. One patient in the placebo group had an acute (defined as onset within 30 days before CSF sampling) relapse with onset 13 days prior to CSF sampling at month 12. In line with the phase 3 study results,<sup><xref rid="R7" ref-type="bibr">7</xref></sup> fingolimod treatment led to reductions in relapses and MRI new lesion formation; however, the small sample size allowed for only qualitative comparisons.</p><table-wrap id="T1" position="float"><label>Table</label><caption><p>Baseline and month 12 results</p></caption><graphic xlink:href="NEUROLOGY2014598144TT1"/></table-wrap><sec id="s2-1"><title>Effect of fingolimod treatment on NfL levels.</title><p>NfL levels at baseline were comparable across the treatment groups (0.5 mg: 644 pg/mL; 1.25 mg: 659 pg/mL; pooled fingolimod 0.5/1.25 mg: 652 pg/mL; placebo: 886 pg/mL; <italic>p</italic> value [fingolimod vs placebo] = 0.619, 0.495, and 0.481, respectively) (<xref ref-type="fig" rid="F1">figure 1A</xref>). By month 12, NfL levels decreased as compared to baseline in the fingolimod-treated groups (0.5 mg: median change from baseline: &#x02212;346 pg/mL [88.9% with reduction], <italic>p</italic> = 0.039, <xref ref-type="fig" rid="F2">figure 2A</xref>; 1.25 mg: &#x02212;313 pg/mL [80.0% with reduction], <italic>p</italic> = 0.035, <xref ref-type="fig" rid="F2">figure 2B</xref>; and pooled fingolimod 0.5/1.25 mg: &#x02212;326 pg/mL [83.3% with reduction], <italic>p</italic> = 0.002), while the median reduction in the placebo group between baseline and month 12 was not significantly different from zero (&#x02212;214 pg/mL [66.7% with reduction], <italic>p</italic> = 0.388, <xref ref-type="fig" rid="F2">figure 2C</xref>). At month 12, NfL levels were lower in the pooled fingolimod group than placebo (<italic>p</italic> = 0.022, <xref ref-type="fig" rid="F1">figure 1B</xref>; <italic>p</italic> = 0.028, for rank ANCOVA including baseline NfL level adjustment as a sensitivity analysis).</p><fig id="F1" position="float"><label>Figure 1</label><caption><title>Neurofilament light chain levels at baseline and after 12 months, cross-sectional analysis</title><p>Neurofilament light chain (NfL) levels at baseline (A); pooled fingolimod 0.5/1.25 mg: 652 pg/mL; placebo: 886 pg/mL, <italic>p</italic> = 0.481. At 12 months (B), NfL levels pooled fingolimod group: 335 pg/mL; placebo: 738 pg/mL, <italic>p</italic> = 0.022. *Mann-Whitney test. **Sign test: baseline vs month 12. Dots represent individual samples. Box and whiskers plotted according to the Tukey method.</p></caption><graphic xlink:href="NEUROLOGY2014598144FF1"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Patient profiles of changes in neurofilament light chain levels from baseline to month 12</title><p>Median change from baseline in neurofilament light chain (NfL) levels at month 12: (A) fingolimod 0.5 mg: &#x02212;346 pg/mL, <italic>p</italic> = 0.039; (B) fingolimod 1.25 mg: &#x02212;313 pg/mL, <italic>p</italic> = 0.035; (C) placebo &#x02212;214 pg/mL, <italic>p</italic> = 0.388. Patient W: Expanded Disability Status Scale score (EDSS) decreased from 2 to 1.5; reduction in gadolinium-enhancing (Gd+) lesions from 5 to 0; decrease in T2 lesion volume (12,309 mm<sup>3</sup>&#x02013;11,828 mm<sup>3</sup>) and no relapses. Patient X: stable EDSS score of 1.5; no Gd+ lesions (both time points); stable T2 lesion volume (5,153 mm<sup>3</sup>&#x02013;5,159 mm<sup>3</sup>) and no relapses. Patient Y: EDSS from 1.5 to 4.5; reduction in Gd+ lesions from 1 to 0; increase in T2 lesion volume (6,512 mm<sup>3</sup>&#x02013;23,794 mm<sup>3</sup>); 2 relapses. Patient Z: increase in EDSS (3&#x02013;4.5); increase in Gd+ lesions from 1 to 7; increase in T2 lesion volume (5,888 mm<sup>3</sup>&#x02013;6,569 mm<sup>3</sup>); 2 relapses.</p></caption><graphic xlink:href="NEUROLOGY2014598144FF2"/></fig></sec><sec id="s2-2"><title>Evaluation of NfL outliers.</title><p>Four patients, 1 each in the placebo and fingolimod 0.5 mg groups and 2 in the fingolimod 1.25 mg group, showed extreme changes in NfL levels at month 12 compared with baseline (<xref ref-type="fig" rid="F2">figure 2, A&#x02013;C</xref>). The overall results were not affected by exclusion of these outlier patients from the analysis (data not shown).</p><p>Patients W (<xref ref-type="fig" rid="F2">figure 2A</xref>) and X (<xref ref-type="fig" rid="F2">figure 2B</xref>) in the fingolimod groups showed a marked reduction in NfL levels at month 12 vs baseline. These were paralleled by clinical and paraclinical improvements over the 12-month observation period. Patient Y (<xref ref-type="fig" rid="F2">figure 2B</xref>) experienced a marked increase in NfL levels, paralleled by 2 relapses, an increase in Expanded Disability Status Scale (EDSS) score, and T2 lesion volume. This patient subsequently discontinued from the study drug after 6.4 months due to an adverse event. Patient Z (placebo; <xref ref-type="fig" rid="F2">figure 2C</xref>) experienced an increase in NfL levels at month 12 compared with baseline and a corresponding increase in EDSS.</p></sec><sec id="s2-3"><title>Correlation analysis.</title><p>Baseline CSF NfL levels did not correlate with age (<italic>r</italic> = &#x02212;0.10, <italic>p</italic> = 0.57) or sex, although trending to higher values in men (women: 576 pg/mL [426&#x02013;920], men: 1,028 pg/mL [659&#x02013;1,297], <italic>p</italic> = 0.077).</p><p>Month 12 NfL levels were higher in patients who experienced relapses during the study (1,448 pg/mL [494&#x02013;3,999]) vs those who did not (384 pg/mL [285&#x02013;698], <italic>p</italic> = 0.014). In patients receiving placebo, month 12 NfL correlated with month 12 EDSS (<italic>r</italic> = 0.65, <italic>p</italic> = 0.021, n = 12) as well as EDSS change from baseline to month 12 (<italic>r</italic> = 0.58, <italic>p</italic> = 0.047, n = 12). Similar correlations did not reach statistical significance in the entire cohort or for patients treated with fingolimod.</p><p>Across all groups, patients with higher baseline NfL levels had a larger T2 lesion volume at baseline (<italic>r</italic> = 0.40, <italic>p</italic> = 0.015). Month 12 NfL levels and new/enlarging T2 lesions count (<italic>r</italic> = 0.57, <italic>p</italic> &#x0003c; 0.001) were also correlated. Patients with higher NfL levels had lower normalized brain volume (<italic>r</italic> = &#x02212;0.41, <italic>p</italic> = 0.014) across all groups at baseline. Correlations of percentage brain volume change from baseline to months 12 and 24 and from months 12 to 24 with baseline NfL levels in both fingolimod (<italic>r</italic><sub>M12</sub> = &#x02212;0.21, <italic>p</italic> = 0.326; <italic>r</italic><sub>M24</sub> = &#x02212;0.39, <italic>p</italic> = 0.058; <italic>r</italic><sub>M12&#x02013;M24</sub> = &#x02212;0.53, <italic>p</italic> = 0.008, n = 24) and placebo (<italic>r</italic><sub>M12</sub> = &#x02212;0.17, <italic>p</italic> = 0.602; <italic>r</italic><sub>M24</sub> = &#x02212;0.47, <italic>p</italic> = 0.124; <italic>r</italic><sub>M12&#x02013;M24</sub> = &#x02212;0.45, <italic>p</italic> = 0.14, n = 12) groups, except in one instance, did not reach statistical significance.</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>Our data show that CSF NfL levels decreased substantially in fingolimod-treated patients but not in patients on placebo. The treatment effect on NfL levels was associated with improved clinical and MRI outcomes. At the individual patient level, extreme changes in CSF NfL levels, irrespective of treatment, were reflected in the clinical and paraclinical findings.</p><p>We did observe a weak reduction of NfL levels in the placebo group, which could either represent a regression to the mean effect, given that the study inclusion criteria selected for patients with active disease before baseline, or possibly just a random variation in NfL levels. Regardless of its cause, this reduction was not statistically significant, and NfL levels were considerably lower in fingolimod-treated patients vs placebo at month 12, even in the less sensitive across-group comparison. Also, baseline NfL levels were slightly higher in the placebo group compared to both fingolimod groups. However, to the extent that this difference could have potentially influenced the results, the tendency probably would have been expected to decrease the evidence of a treatment effect (i.e., because it is more difficult to see improvement in a group starting with lower baseline values). In addition, a rank ANCOVA analysis that adjusted for baseline yielded similar evidence of an effect (<italic>p</italic> = 0.028).</p><p>Consistent with our study results, a recent uncontrolled study in patients with RRMS with high disease activity suggested an association of natalizumab treatment with a decrease in CSF NfL levels and corresponding improvements in clinical, MRI, and other laboratory measures.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> Our study confirms in a placebo-controlled study setting that immunomodulatory therapies can impact on CSF NfL levels. Taken together, the role of CSF NfL quantification as a measure of neuroaxonal damage is corroborated by the observed association with MRI markers of disease activity, and the trend for an association with the development of brain volume loss, adding to the body of previous evidence. Pronounced changes in NfL levels with fingolimod therapy as opposed to placebo further suggest the usefulness of NfL levels as a putative biomarker of axonal damage in MS clinical trials. The reduction of NfL levels by treatment could either be related to the well-known immunomodulatory effects of fingolimod or to potential direct effects of the drug on CNS cells.<sup><xref rid="R6" ref-type="bibr">6</xref></sup></p><p>Limitations of this study include the post hoc nature of the analyses and the small sample size. The latter is driven by the limited number of paired CSF samples available from the FREEDOMS trial. It is unclear if the results found in this sample would be mirrored by the full study population. The findings of this study are of interest and serve to generate hypotheses about the utility of NfL as a biomarker of disease activity, tissue damage, and treatment effect. Our results support the need for future larger scale studies including CSF sampling and investigating easier accessible compartments like peripheral blood to further examine the utility of NfL levels as a potential biomarker in MS.<sup><xref rid="R10" ref-type="bibr">10</xref></sup></p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Accompanying Editorial</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_84_16_1639__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf"
xlink:href="supp_WNL.0000000000001491_1620.pdf"/>
</supplementary-material>
</sec>
</body><back><fn-group><fn fn-type="other"><p>Editorial, page <related-article related-article-type="commentary" id="d35e2228" vol="84" page="1620" issue="16" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="25809305" ext-link-type="pubmed">1620</related-article></p></fn></fn-group><ack><title>ACKNOWLEDGMENT</title><p>The authors thank Hedwig Wariwoda and Rocco Adiutori for technical support; and Rishard Salie, Novartis Pharma AG, for coordinating author review and feedback on the draft manuscript, and organizing author discussions.</p></ack><sec sec-type="contributions"><title>AUTHOR CONTRIBUTIONS</title><p content-type="contributions">All authors drafted/revised the manuscript for intellectual content. J. Kuhle, G. Francis, G. Giovannoni, and L. Kappos conceptualized and designed the study. J. Kuhle and Y. Chen conducted statistical analysis of the data from the study. Authors who carried out the biostatistical analysis: J. Kuhle, Neuroimmunology Unit, Blizard Institute Barts, and the London School of Medicine and Dentistry, London, UK, and Neurology, University Hospital Basel, Switzerland; and Y. Chen, Novartis Pharmaceuticals Corporation, East Hanover, NJ.</p></sec><sec sec-type="funding"><title>STUDY FUNDING</title><p content-type="funding">Funded by the <funding-source>University Hospital Basel and Novartis Pharma AG</funding-source>, <funding-source>Basel</funding-source>.</p></sec><sec sec-type="disclosure"><title>DISCLOSURE</title><p content-type="disclosure">J. Kuhle is supported by an <funding-source>ECTRIMS Research Fellowship Programme</funding-source> and by the <funding-source>Forschungsfonds of the University of Basel</funding-source>, Switzerland; has received research support from the <funding-source>Swiss MS Society</funding-source>, <funding-source>Swiss ALS Society</funding-source>, <funding-source>Protagen AG</funding-source>, <funding-source>Roche</funding-source>, and <funding-source>Novartis</funding-source>; and served on scientific advisory boards for <funding-source>Genzyme</funding-source>/<funding-source>Sanofi-Aventis</funding-source>, <funding-source>Merck Serono</funding-source>, and <funding-source>Novartis Pharma</funding-source>. G. Disanto and J. Lorscheider report no disclosures relevant to the manuscript. T. Stites is an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ. Y. Chen is an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ. F. Dahlke is an employee of Novartis Pharma AG, Basel, Switzerland. G. Francis is an employee of Novartis Pharmaceuticals Corporation, East Hanover, NJ. A. Shrinivasan is an employee of Novartis Healthcare Pvt Ltd, Hyderabad, India. E. Radue has received honoraria for serving as speaker at scientific meetings and consultant for Novartis, Biogen Idec, Merck Serono, and Bayer Schering. He has received financial support for research activities from <funding-source>Actelion</funding-source>, <funding-source>Basilea Pharmaceutica Ltd</funding-source>, <funding-source>Biogen Idec</funding-source>, <funding-source>Merck Serono</funding-source>, and <funding-source>Novartis</funding-source>. G. Giovannoni has received research grant support from <funding-source>Bayer-Schering Healthcare</funding-source>, <funding-source>Biogen-Idec</funding-source>, <funding-source>GW Pharma</funding-source>, <funding-source>Merck Serono</funding-source>, <funding-source>Merz</funding-source>, <funding-source>Novartis</funding-source>, <funding-source>Teva</funding-source>, and <funding-source>Sanofi-Aventis</funding-source>. He has received personal compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees, and data and safety monitoring committees from Bayer-Schering Healthcare, Biogen-Idec, Eisai, Elan, Fiveprime, Genzyme, Genentech, GSK, GW Pharma, Ironwood, Merck-Serono, Novartis, Pfizer, Roche, Sanofi-Aventis, Synthon BV, Teva, UCB Pharma, and Vertex Pharmaceuticals. L. Kappos' institution, University Hospital Basel, received research support from <funding-source>Actelion</funding-source>, <funding-source>Advancell</funding-source>, <funding-source>Allozyne</funding-source>, <funding-source>BaroFold</funding-source>, <funding-source>Bayer Health Care Pharmaceuticals</funding-source>, <funding-source>Bayer Schering Pharma</funding-source>, <funding-source>Bayhill</funding-source>, <funding-source>Biogen Idec</funding-source>, <funding-source>BioMarin</funding-source>, <funding-source>CSL Behring</funding-source>, <funding-source>Elan</funding-source>, <funding-source>Genmab</funding-source>, <funding-source>Genmark</funding-source>, <funding-source>GeNeuro SA</funding-source>, <funding-source>GlaxoSmithKline</funding-source>, <funding-source>Lilly</funding-source>, <funding-source>Merck Serono</funding-source>, <funding-source>MediciNova</funding-source>, <funding-source>Novartis</funding-source>, <funding-source>Novo Nordisk</funding-source>, <funding-source>Peptimmune</funding-source>, <funding-source>sanofi-aventis</funding-source>, <funding-source>Santhera</funding-source>, <funding-source>Roche</funding-source>, <funding-source>Teva</funding-source>, <funding-source>UCB</funding-source>, <funding-source>Wyeth</funding-source>, the <funding-source>Swiss MS Society</funding-source>, the <funding-source>Swiss National Research Foundation</funding-source>, the <funding-source>European Union</funding-source>, and the <funding-source>Gianni Rubatto</funding-source>, <funding-source>Novartis</funding-source>, and <funding-source>Roche Research Foundations</funding-source>. Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link> for full disclosures.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id="G1">ANCOVA</term><def><p>analysis of covariance</p></def></def-item><def-item><term id="G2">EDSS</term><def><p>Expanded Disability Status Scale</p></def></def-item><def-item><term id="G3">FREEDOMS</term><def><p>Fingolimod (FTY720) Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis</p></def></def-item><def-item><term id="G4">MS</term><def><p>multiple sclerosis</p></def></def-item><def-item><term id="G5">Nf</term><def><p>neurofilaments</p></def></def-item><def-item><term id="G6">NfH</term><def><p>heavy chain subunit of neurofilaments</p></def></def-item><def-item><term id="G7">NfL</term><def><p>light chain subunit of neurofilaments</p></def></def-item><def-item><term id="G8">RRMS</term><def><p>relapsing-remitting multiple sclerosis</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petzold</surname><given-names>A</given-names></name></person-group>
<article-title>Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss</article-title>. <source>J Neurol Sci</source>
<year>2005</year>;<volume>233</volume>:<fpage>183</fpage>&#x02013;<lpage>198</lpage>.<pub-id pub-id-type="pmid">15896809</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Confavreux</surname><given-names>C</given-names></name><name><surname>Vukusic</surname><given-names>S</given-names></name></person-group>
<article-title>Natural history of multiple sclerosis: a unifying concept</article-title>. <source>Brain</source>
<year>2006</year>;<volume>129</volume>:<fpage>606</fpage>&#x02013;<lpage>616</lpage>.<pub-id pub-id-type="pmid">16415308</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhle</surname><given-names>J</given-names></name><name><surname>Plattner</surname><given-names>K</given-names></name><name><surname>Bestwick</surname><given-names>JP</given-names></name><etal/></person-group>
<article-title>A comparative study of CSF neurofilament light and heavy chain protein in MS</article-title>. <source>Mult Scler</source>
<year>2013</year>;<volume>19</volume>:<fpage>1597</fpage>&#x02013;<lpage>1603</lpage>.<pub-id pub-id-type="pmid">23529999</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunnarsson</surname><given-names>M</given-names></name><name><surname>Malmestrom</surname><given-names>C</given-names></name><name><surname>Axelsson</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab</article-title>. <source>Ann Neurol</source>
<year>2011</year>;<volume>69</volume>:<fpage>83</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">21280078</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhle</surname><given-names>J</given-names></name><name><surname>Malmestrom</surname><given-names>C</given-names></name><name><surname>Axelsson</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis</article-title>. <source>Acta Neurol Scand</source>
<year>2013</year>;<volume>128</volume>:<fpage>e33</fpage>&#x02013;<lpage>e36</lpage>.<pub-id pub-id-type="pmid">23763388</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miron</surname><given-names>VE</given-names></name><name><surname>Ludwin</surname><given-names>SK</given-names></name><name><surname>Darlington</surname><given-names>PJ</given-names></name><etal/></person-group>
<article-title>Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices</article-title>. <source>Am J Pathol</source>
<year>2010</year>;<volume>176</volume>:<fpage>2682</fpage>&#x02013;<lpage>2694</lpage>.<pub-id pub-id-type="pmid">20413685</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Radue</surname><given-names>EW</given-names></name><name><surname>O'Connor</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source>
<year>2010</year>;<volume>362</volume>:<fpage>387</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">20089952</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JA</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Comi</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis</article-title>. <source>N Engl J Med</source>
<year>2010</year>;<volume>362</volume>:<fpage>402</fpage>&#x02013;<lpage>415</lpage>.<pub-id pub-id-type="pmid">20089954</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabresi</surname><given-names>PA</given-names></name><name><surname>Radue</surname><given-names>EW</given-names></name><name><surname>Goodin</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial</article-title>. <source>Lancet Neurol</source>
<year>2014</year>;<volume>13</volume>:<fpage>545</fpage>&#x02013;<lpage>556</lpage>.<pub-id pub-id-type="pmid">24685276</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaiottino</surname><given-names>J</given-names></name><name><surname>Norgren</surname><given-names>N</given-names></name><name><surname>Dobson</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Increased neurofilament light chain blood levels in neurodegenerative neurological diseases</article-title>. <source>PLoS One</source>
<year>2013</year>;<volume>8</volume>:<fpage>e75091</fpage>.<pub-id pub-id-type="pmid">24073237</pub-id></mixed-citation></ref></ref-list></back></article>